Rosa T van der Kaaij1, Petur Snaebjornsson2, Francine E M Voncken3, Jolanda M van Dieren4, Edwin P M Jansen5, Karolina Sikorska6, Annemieke Cats7, Johanna W van Sandick8. 1. Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: r.vd.kaaij@nki.nl. 2. Department of Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: p.snaebjornsson@nki.nl. 3. Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: f.voncken@nki.nl. 4. Department of Gastroenterology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: j.v.dieren@nki.nl. 5. Department of Radiation Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: epm.jansen@nki.nl. 6. Department of Biometrics, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: k.sikorska@nki.nl. 7. Department of Gastroenterology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: a.cats@nki.nl. 8. Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address: j.v.sandick@nki.nl.
Abstract
AIM: To investigate the histological subtypes of oesophageal adenocarcinoma according to the Laurén classification (intestinal/diffuse/mixed) in relation to tumour response to neoadjuvant treatment, and in relation to patients' survival after potentially curative treatment. METHODS: Data were collected from all oesophageal adenocarcinoma patients who underwent potentially curative treatment in our institute between 1998 and 2014. Treatment consisted of neoadjuvant chemoradiotherapy (36-50 Gy) followed by an oesophagectomy or definitive chemoradiotherapy (50-50.4 Gy). Clinical data were collected from patient records. All endoscopic biopsies and surgical resection specimens were reassessed to determine the histological subtype (intestinal, diffuse or mixed) and the Mandard tumour regression grade (TRG). The impact of the histological subtypes on survival was determined using a Cox model. RESULTS: Median follow-up was 68 months. Diffuse and mixed type cancers accounted for 25% of oesophageal adenocarcinomas. Median overall survival differed significantly between patients with intestinal (n = 121, 39 months), diffuse (n = 28, 18 months) or mixed type (n = 11, 25 months) carcinomas (log rank, p = 0.023). In multivariable analysis, the diffuse type was associated with shorter survival (diffuse versus intestinal: hazard ratios 2.06, p = 0.006). A pathologically (near) complete response (TRG 1 or 2) was seen less frequently in diffuse type than in intestinal type carcinomas (24% versus 60%; p = 0.015). CONCLUSIONS: Patients with diffuse type oesophageal adenocarcinomas had a significantly worse prognosis than those with intestinal type carcinomas. Intestinal type carcinomas showed a better response to neoadjuvant chemoradiotherapy than diffuse type carcinomas. These differences call for the exploration of differentiated approaches in the potentially curative treatment of oesophageal adenocarcinomas.
AIM: To investigate the histological subtypes of oesophageal adenocarcinoma according to the Laurén classification (intestinal/diffuse/mixed) in relation to tumour response to neoadjuvant treatment, and in relation to patients' survival after potentially curative treatment. METHODS: Data were collected from all oesophageal adenocarcinomapatients who underwent potentially curative treatment in our institute between 1998 and 2014. Treatment consisted of neoadjuvant chemoradiotherapy (36-50 Gy) followed by an oesophagectomy or definitive chemoradiotherapy (50-50.4 Gy). Clinical data were collected from patient records. All endoscopic biopsies and surgical resection specimens were reassessed to determine the histological subtype (intestinal, diffuse or mixed) and the Mandard tumour regression grade (TRG). The impact of the histological subtypes on survival was determined using a Cox model. RESULTS: Median follow-up was 68 months. Diffuse and mixed type cancers accounted for 25% of oesophageal adenocarcinomas. Median overall survival differed significantly between patients with intestinal (n = 121, 39 months), diffuse (n = 28, 18 months) or mixed type (n = 11, 25 months) carcinomas (log rank, p = 0.023). In multivariable analysis, the diffuse type was associated with shorter survival (diffuse versus intestinal: hazard ratios 2.06, p = 0.006). A pathologically (near) complete response (TRG 1 or 2) was seen less frequently in diffuse type than in intestinal type carcinomas (24% versus 60%; p = 0.015). CONCLUSIONS:Patients with diffuse type oesophageal adenocarcinomas had a significantly worse prognosis than those with intestinal type carcinomas. Intestinal type carcinomas showed a better response to neoadjuvant chemoradiotherapy than diffuse type carcinomas. These differences call for the exploration of differentiated approaches in the potentially curative treatment of oesophageal adenocarcinomas.
Authors: D J Crull; M C H Hogenes; R Hoekstra; E M Hendriksen; M J van Det; E A Kouwenhoven Journal: Ann Surg Oncol Date: 2022-01-29 Impact factor: 5.344
Authors: Richard C Turkington; Laura A Knight; Jaine K Blayney; Maria Secrier; Rosalie Douglas; Eileen E Parkes; Eilis K Sutton; Leanne Stevenson; Damian McManus; Sophia Halliday; Andrena M McCavigan; Gemma E Logan; Steven M Walker; Christopher J Steele; Juliane Perner; Jan Bornschein; Shona MacRae; Ahmad Miremadi; Eamon McCarron; Stephen McQuaid; Kenneth Arthur; Jacqueline A James; Martin M Eatock; Robert O'Neill; Fergus Noble; Timothy J Underwood; D Paul Harkin; Manuel Salto-Tellez; Rebecca C Fitzgerald; Richard D Kennedy Journal: Gut Date: 2019-03-09 Impact factor: 23.059
Authors: Astrid E Slagter; Marieke A Vollebergh; Edwin P M Jansen; Johanna W van Sandick; Annemieke Cats; Nicole C T van Grieken; Marcel Verheij Journal: Front Oncol Date: 2020-11-30 Impact factor: 6.244
Authors: Rebekka Schirren; Alexander Novotny; Christian Oesterlin; Julia Slotta-Huspenina; Helmut Friess; Daniel Reim Journal: Cancers (Basel) Date: 2021-01-14 Impact factor: 6.639
Authors: Rebekka Schirren; Alexander Novotny; Julia Slotta-Huspenina; Helmut Friess; Daniel Reim Journal: Cancers (Basel) Date: 2021-03-15 Impact factor: 6.639
Authors: Eliza Hagens; Karina Tukanova; Sara Jamel; Mark van Berge Henegouwen; George B Hanna; Suzanne Gisbertz; Sheraz R Markar Journal: Dis Esophagus Date: 2022-01-07 Impact factor: 3.429